Recent events
Recent events tied to this brand in public sources.
Back to profile29 entries · Page 2 of 2
2020
FDA approves BMS's Onureg for AML continuation therapy
The FDA approved Bristol-Myers Squibb's Onureg for the continuation treatment setting of acute myeloid leukemia in eligible patients.
2020
FDA approves Opdivo for advanced esophageal cancer after chemotherapy
The FDA approved nivolumab (Opdivo) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after fluoropyrimidine- and platinum-based chemotherapy. The source identifies Bristol-Myers Squibb as the manufacturer.
2020
FDA approves Reblozyl for certain patients with myelodysplastic syndromes
The FDA approved Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) to treat patients with myelodysplastic syndromes who require red blood cell transfusions and have failed an erythropoiesis-stimulating agent. The article reports that the approval was based on phase 3 trial results.
2020
China suspends imports, sales and use of Bristol Myers Squibb paclitaxel product
China's National Medical Products Administration announced a suspension of imports, sales and use of Bristol Myers Squibb's albumin-bound paclitaxel product, based on inspection findings at a U.S. contract manufacturing facility.
2020
BeiGene expects temporary ABRAXANE supply interruption in China
BeiGene said it expected the regulatory suspension of Bristol Myers Squibb's albumin-bound paclitaxel product to cause a temporary interruption in China's supply of ABRAXANE. BeiGene said it was working with Bristol Myers Squibb on corrective work at the existing production site and an application to supply China from another factory.
2020
Bristol-Myers Squibb and Voluntis collaborate on oncology digital therapeutics
Bristol-Myers Squibb and Voluntis entered a collaboration to co-develop digital therapeutics for oncology, including solutions intended to support cancer patients and a planned mobile app for treatment support and symptom tracking.
2019
Fitbit, Bristol Myers Squibb and Pfizer announce AFib detection collaboration
Bristol Myers Squibb and Pfizer, operating as the BMS-Pfizer Alliance, and Fitbit said they would collaborate to improve earlier detection of atrial fibrillation. They planned to create AFib detection software for Fitbit devices and submit it to the Food and Drug Administration.
2019
Bristol Myers Squibb completes acquisition of Celgene
Bristol Myers Squibb completed its acquisition of Celgene. Celgene became a wholly owned subsidiary of Bristol Myers Squibb.
2017
Merck settles PD-1 patent litigation with BMS and Ono
Merck agreed to pay Bristol-Myers Squibb and Ono Pharmaceutical $625 million and royalties on Keytruda sales to settle patent infringement litigation concerning PD-1 inhibitors. The agreement provided for dismissal of the patent litigation filed against Merck.